OBJECTIVES: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. METHODS: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. RESULTS: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-gamma producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. CONCLUSION: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-gamma producing memory cells after booster immunization.
OBJECTIVES: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. METHODS: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. RESULTS: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-gamma producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. CONCLUSION: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-gamma producing memory cells after booster immunization.
Authors: Ronald J Bosch; Richard B Pollard; Alan Landay; Evgenia Aga; Lawrence Fox; Ronald Mitsuyasu Journal: J Interferon Cytokine Res Date: 2011-02-03 Impact factor: 2.607
Authors: Jakob Michaëlsson; Brian R Long; Christopher P Loo; Lewis L Lanier; Gerald Spotts; Frederick M Hecht; Douglas F Nixon Journal: J Infect Dis Date: 2008-01-01 Impact factor: 5.226
Authors: Ping Jin; Ena Wang; Maurizio Provenzano; Sara Deola; Silvia Selleri; Jiaqiang Ren; Sonia Voiculescu; David Stroncek; Monica C Panelli; Francesco M Marincola Journal: J Transl Med Date: 2006-06-28 Impact factor: 5.531
Authors: Gareth Ad Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén Mi Aasa-Chapman; Brian Gazzard; Frances M Gotch Journal: J Immune Based Ther Vaccines Date: 2007-04-11